Full text
Earnings transcript
Read the complete earnings call transcript.
DHR
Danaher Corporation
$217.92
2.56
(1.19%)
| Exchange: | NYSE |
| Market Cap: | 153.195B |
| Shares Outstanding: | 320M |
Delayed data
About The Company
| Sector: | Healthcare | |||||
| Industry: | Medical – Diagnostics & Research | |||||
| CEO: | Rainer Blair | |||||
| Full Time Employees: | 59000 | |||||
| Address: |
| |||||
| Website: | https://www.danaher.com |
Danaher Corporation is a diversified global technology and science company that specializes in developing, manufacturing, and distributing a wide array of professional, medical, industrial, and commercial products and services across the world. The organization is structured into three primary operating segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. Within the Life Sciences segment, Danaher provides advanced instrumentation and solutions crucial for scientific research and development. This encompasses equipment like mass spectrometers, flow cytometry, genomics, lab automation, centrifugation, particle counting and characterization tools, and microscopes, alongside genomics consumables and technologies vital for Gene and Cell Therapy. Additionally, it delivers bioprocess technologies, consumables, and related services, as well as sophisticated filtration, separation, and purification systems. Its diverse clientele includes pharmaceutical, biopharmaceutical, food and beverage, medical, and life sciences companies, in addition to universities, medical schools, research institutions, and various industrial manufacturers. The Diagnostics segment is dedicated to furnishing essential tools for healthcare. Its offerings range from comprehensive systems for chemistry, immunoassay, microbiology, and automation to products for hematology, molecular, acute care, and pathology diagnostics. This segment equips hospitals, physicians’ offices, reference laboratories, and other critical care settings with clinical instruments, reagents, consumables, software, and support services for accurate patient diagnosis and management. The Environmental & Applied Solutions segment addresses a broad spectrum of industrial and resource management requirements. It supplies instrumentation, consumables, software, services, and disinfection systems critical for the analysis, treatment, and management of various water types—including ultra-pure, potable, industrial, waste, ground, source, and ocean water—across residential, commercial, industrial, and natural resource applications. Furthermore, this segment delivers instruments, software, services, and consumables tailored for color and appearance management, packaging design and quality assurance, packaging converting, printing, marking, coding, and traceability applications for consumer, pharmaceutical, and industrial products. Established in 1969, the company was initially known as Diversified Mortgage Investors, Inc., before officially rebranding as Danaher Corporation in 1984. Its corporate headquarters are located in Washington, D.C.
Click to read more…
Revenue Segmentation
EPS
Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.
Earnings Call
AI summary
Key takeaways
Short, structured highlights from the call so you can focus on what matters.
Log in to continue
Log in to read the full transcript and AI-generated earnings summaries.
Login — it's freeIncome Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | 23,890,000 | 23,875,000 | 24,568,000 |
| Gross Profit | 14,034,000 | 14,206,000 | 14,970,000 |
| EBITDA | 7,499,000 | 7,276,000 | 6,945,000 |
| Operating Income | 5,279,000 | 5,184,000 | 5,137,000 |
| Net Income | 4,764,000 | 3,899,000 | 3,614,000 |
(* All numbers are in thousands)
Balance Sheet
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Total Assets | 84,488,000 | 77,542,000 | 83,464,000 |
| Total Liabilities | 30,998,000 | 27,992,000 | 30,930,000 |
| Total Stockholders Equity | 53,486,000 | 49,543,000 | 52,534,000 |
| Total Debt | 19,536,000 | 17,146,000 | 18,418,000 |
| Cash and Cash Equivalents | 5,864,000 | 2,078,000 | 4,615,000 |
(* All numbers are in thousands)
Cash Flow Statement
| Year | 2023 | 2024 | 2025 |
|---|---|---|---|
| Operating Cash Flow | 7,164,000 | 6,688,000 | 6,416,000 |
| Capital Expenditure | -1,383,000 | -1,392,000 | -1,156,000 |
| Free Cash Flow | 5,781,000 | 5,296,000 | 5,260,000 |
| Net Income | 4,221,000 | 3,899,000 | 3,614,000 |
| Net Change in Cash | -131,000 | -3,786,000 | 2,537,000 |
(* All numbers are in thousands)
Analyst Estimates
| Fiscal Year | 2030 | Research Access | Research Access | Research Access | Research Access |
|---|---|---|---|---|---|
| Estimated Revenue (Low) | 33,118,306.067 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (High) | 34,387,907.594 | Research Access | Research Access | Research Access | Research Access |
| Estimated Revenue (Avg) | 33,857,500 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Low) | 10,578,654.988 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (High) | 10,984,191.325 | Research Access | Research Access | Research Access | Research Access |
| Estimated Ebitda (Avg) | 10,814,768.440 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Low) | 8,621,436.702 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (High) | 9,053,987.772 | Research Access | Research Access | Research Access | Research Access |
| Estimated Net Income (Avg) | 8,873,280.012 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Low) | 9,900,573.473 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (High) | 10,280,115.324 | Research Access | Research Access | Research Access | Research Access |
| Estimated SGA Expense (Avg) | 10,121,552.282 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Avg) | 12.480 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (High) | 12.730 | Research Access | Research Access | Research Access | Research Access |
| Estimated EPS (Low) | 12.130 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated Revenue) | 14 | Research Access | Research Access | Research Access | Research Access |
| Number of Analysts (Estimated EPS) | 4 | Research Access | Research Access | Research Access | Research Access |
Log in to continue
Log in and subscribe to Full Access to see up to 5 years of analyst estimates.
Login — it's free(* All numbers are in thousands)
Current Key Metrics
Log in to continue
Log in to see all key valuation metrics and ratios for this symbol.
Login — it's freeForward P/E Ratios
Log in to continue
Log in with Full Access for forward P/E high/low estimates and the full multi-year table.
Login — it's freeSWOT Analysis
At what price to buy it? -
Intrinsic Value Calculator
Based on current fundamentals and analyst forecasts, MARKETSnap estimates DHR intrinsic value between $105.71 – $154.44 per share. This depends on revenue growth, margins, and discount rate.
This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.
[intrinsic_calculator]
Common questions about DHR valuation
Is Danaher Corporation (DHR) overvalued or undervalued right now?
MARKETSnap estimates intrinsic value for Danaher Corporation (DHR) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.
Is DHR a buy, hold, or sell for long-term investors?
MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether DHR trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.
What is DHR’s P/E ratio?
You can see DHR’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.
How is intrinsic value calculated for DHR?
MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.
Is DHR a good long-term investment?
Whether DHR fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.
DHR
1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.
Daily snapshot
1.19
Trading Metrics:
| Open: | 214.78 | Previous Close: | — | |
| Day Low: | — | Day High: | — | |
| Year Low: | Year High: | |||
| Price Avg 50: | Price Avg 200: | |||
| Volume: | Average Volume: |
Log in to continue
Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.
Login — it's free
